FR255734

In vitro studies have shown that FR255734 effectively blocked T-cell proliferation and proinflammatory cytokine production. These observations warrant studies to evaluate the efficacy of FR255734 in human autoimmune diseases.

Also Known As:

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hanaoka, Kaori: 1 article (08/2008)
2.	Herzenberg, Leonard A: 1 article (08/2008)
3.	Herzenberg, Leonore A: 1 article (08/2008)
4.	Jiang, Wen-Yue: 1 article (08/2008)
5.	Kubo, Kaori: 1 article (08/2008)
6.	Kundu-Raychaudhuri, Smriti: 1 article (08/2008)
7.	Masunaga, Taro: 1 article (08/2008)
8.	Raychaudhuri, Siba P: 1 article (08/2008)
9.	Tamura, Kouichi: 1 article (08/2008)

Related Diseases

1.	Autoimmune Diseases (Autoimmune Disease) 08/01/2008 - "These observations warrant studies to evaluate the efficacy of FR255734 in human autoimmune diseases."
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 08/01/2008 - "FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model." 08/01/2008 - "Here, using the severe combined immunodeficient (SCID) mouse-psoriasis xenograft model, we report therapeutic efficacy of a humanized anti-CD28 monoclonal antibody (FR255734; Astellas Pharmaceuticals Inc., Tokyo, Japan). " 08/01/2008 - "Transplanted psoriasis plaques on the SCID mouse were treated weekly for 4 weeks with intraperitoneal injections of FR255734 at 10, 3, and 1-mg kg(-1) doses. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Dihydrotachysterol (AT 10)

Related Therapies and Procedures

1.	Intraperitoneal Injections